Objectives To determine the prevalence of type 1 diabetes mellitus (T1D) in patients with juvenile idiopathic arthritis (JIA) and to characterize patients having both.
Twin and family studies have emphasized the importance of genetic predisposition for autoimmune diseases (AIDs). [3] [4] [5] Genetic analyses have shown an association between mutations in certain susceptibility gene loci and AIDs. Phenotypically different AIDs share genetic susceptibility factors. 6, 7 Several single nucleotide polymorphisms associated with JIA have been identified. 7 Type 2 diabetes mellitus with 1 AID are at an increased risk for another AID. 11 For example, the genetic association between type 1 diabetes mellitus (T1D) and JIA has been described. 12, 13 Epidemiologic knowledge about the comorbidity of JIA and T1D is limited. Previous studies are based mostly on case reports. [14] [15] [16] A few observational studies have shown an increased frequency of diabetes mellitus (DM) in patients with JIA compared with the general population. 17, 18 Detailed information about the comorbidity of T1D in patients with JIA has been limited. Two established prospective cohorts in Germany, the National Pediatric Rheumatologic Database (NPRD) for JIA and the North Rhine-Westphalian Diabetes Registry for T1D, provide a unique opportunity to investigate the co-occurrence of JIA and T1D.
In 2015, Hermann et al published data on the prevalence of JIA in patients with T1D. They showed an increased prevalence of JIA compared with the general population and an earlier onset of diabetes in patients with JIA. 19 The present study, based on the NPRD data, aimed to determine the prevalence of T1D in patients with JIA and to characterize the features of patients with JIA with T1D vs patients with JIA without T1D.
Methods
The NPRD of children and adolescents with rheumatic diseases was started in 1997 and includes incident and prevalent cases of a wide spectrum of juvenile rheumatic diseases. The majority of enrolled patients (3 of 4 patients) have JIA. Enrolled patients are followed annually by a physician and patient questionnaire. For more details, we refer to previous NPRD publications. [20] [21] [22] Patients with JIA according to the International League of Associations for Rheumatology criteria 23, 24 who were 20 years of age or younger and recorded in the NPRD between 2012 and 2014, were included in this study.
Information about comorbid DM was recorded from 2012 to 2014. The presence of autoimmune thyroiditis (AIT) and celiac disease (CD) was documented by physicians only in 2013 and 2014. An additional short questionnaire on DM was used to confirm the diagnosis of DM and to provide more details regarding T1D. Patients recorded in multiple years were counted only once.
The prevalence of T1D in patients with JIA was compared with the prevalence of T1D in the general population of children and adolescents aged 0-20 years in the federal state of North Rhine-Westphalia on December 31, 2014. Independent registries for T1D exist in 4 federal German states. We chose North Rhine-Westphalia for our comparison because it comprises 22%-23% of all German children and adolescents. The prevalence data of North Rhine-Westphalia were derived from the North Rhine-Westphalian diabetes registry maintained at the German Diabetes Center since 1993. The prevalence of T1D in North Rhine-Westphalia is higher than in other parts of Germany. 25 Incident cases between the ages of 0 and 20 years for the period 2002-2014 were selected from the registry to estimate the cumulative age distribution of T1D onset in the general population compared with the distribution of T1D onset in patients with JIA. This registry ascertains newly diagnosed cases of T1D from 3 data sources: a prospective hospitalbased active surveillance system (Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland [ESPED]), annual inquiries among medical practices (pediatricians, general practitioners, and internal specialists), and the diabetes prospective follow-up (Diabetes-Patienten-Verlaufsdokumentation [DPV]) database. DPV is a computer-based system for longitudinal documentation of treatment and outcomes in routine diabetes care. 26 The DPV software is used in more than 420 diabetes centers in Germany. Completeness of the North Rhine-Westphalian diabetes registry is estimated at 99%.
Sociodemographic and clinical characteristics, and patientreported outcome measures were annually recorded in the NPRD. These included age, sex, body height, and weight, JIA duration, age at JIA onset, JIA category, treatment, and others. Body mass index (BMI) was calculated by dividing body weight (in kg) by squared body height (in meters). Categories of underweight, normal weight, overweight, and obesity were defined according to sex-and age-specific BMI percentile curves for German children as suggested by Kromeyer-Hauschild et al. 27 The physicians recorded treatments with conventional synthetic and biological disease-modifying antirheumatic drugs (DMARD) as well as glucocorticoids, including low dose (<0.2 mg/kg), high dose (≥0.2 mg/kg), and pulse therapy. In addition, physicians recorded comorbidities of DM, AIT, and CD and their onset dates.
The patient's JIA disease activity was assessed by the pediatric rheumatologist using a numeric rating scale (0-10, 0-no disease activity). The clinical Juvenile Arthritis Disease Activity Score (cJADAS) 28 is a composite index for assessment of JIA disease activity. The cJADAS-10 is the sum of the physician's and patient's/parent's global assessment and the number of active joints (maximum = 10). Functional ability was reported by patients or parents using the Childhood Health Assessment Questionnaire, calculated as a disability index ranging between 0 and 3 (0-no disability). 29 The DM questionnaire was sent to pediatric rheumatology centers that recorded a DM case between 2012 and 2014 and included questions regarding the type of DM (T1D, type 2 diabetes mellitus [T2D], steroid-induced diabetes, maturityonset diabetes of the young-type, and others), age at DM diagnosis, insulin treatment, diagnosis of other AIDs (including AIT and CD), and family history of AIDs.
Statistical Analyses
Cross-sectional data from the NPRD for the years 2012, 2013, and 2014 were used to determine the diabetes rate in patients with JIA. Descriptive analyses included absolute and relative frequencies for categorical variables, means and SDs or median and IQR, if appropriate, for continuously distributed variables.
The frequency of T1D in patients with JIA was compared with the population-based data of the North Rhine-Westphalian diabetes registry. 25 Crude diabetes prevalence and respective Volume 192 • January 2018 95% CIs were estimated assuming a Poisson distribution of cases. For comparison between the JIA cohort and the general population, prevalences were indirectly standardized with respect to sex and/or age (age groups 0-4, 5-9, 10-14, and 15-20 years) to the general population of North RhineWestphalia. Standardized prevalence ratios (PRs) with 95% CIs and P values of respective c 2 tests were estimated. 30 We analyzed the cumulative distribution of the age at T1D onset for patients with JIA compared with the general population. For a descriptive subanalysis of JIA treatment before T1D onset, longitudinally collected data from 2000 to 2014 were considered in a subset of patients only, who had been documented at least once before T1D onset. The overall redocumentation rate was approximately 60%, which was the reason longitudinal data were not available for all patients who developed JIA before T1D. Statistical analysis was conducted using SPSS Statistics 23, (IBM SPSS; SPSS Inc, Chicago, Illinois) and SAS v 9.4 (SAS Institute, Cary, North Carolina).
Results
DM was recorded in 62 of 12 269 patients with JIA. Two patients were diagnosed with T2D and 2 patients had maturityonset diabetes of the young and, therefore, were excluded from analysis. Therefore, the prevalence of T1D in the NPRD was 0.47% (95% CI 0.36-0.61). T1D prevalences for sex and age groups are shown in Figure 1 . T1D was significantly more common in patients with JIA than in the general population (PR 1.76 (CI 1.34; 2.28), P < .001). The T1D PR was 1.72 (CI 1.21; 2.38, P = .003) for female patients and 1.83 (CI 1.15; 2.77, P = .012) for male patients. There was no statistically significant difference in the T1D rate between male and female patients. The T1D prevalence ratio differed among the various age groups. The T1D rate ratio among male patients differed with age from 1.73 between 5 and 9 years and 2.18 between 15 and 20 years. Differences between age groups were more pronounced among female patients from 1.12 between 10 and 14 years and 2.78 between 0 and 4 years. Differences between the sexes were not statistically significant.
The sociodemographic and clinical characteristics of patients with JIA with or without T1D are reported in Table I . The differences in the JIA category distribution were not statistically significant between the 2 groups. Patients with JIA without T1D were significantly younger at JIA onset than patients with T1D (P = .032). There were no significant differences in the duration of JIA or in the therapy of both groups. The duration from symptom onset until the first visit to a rheumatologist did not differ between the patient groups.
A comparison of sex-and age-adjusted anthropometric SDS did not reveal differences for height between the groups. Patients without T1D had a lower weight than patients with T1D (P = .042). Both groups had a lower weight than the reference data. The BMI SDS in patients with JIA and T1D (0.17) were significantly higher than the BMI SDS in patients without T1D (-0.25, P = .007). The proportion of overweight/obese patients in the group of patients with JIA and T1D was higher than in those without T1D (14.3% vs 10.8%, respectively). The distribution of the outcome variables (functional disability, physician's global assessment, and cJADAS-10) was comparable between the groups.
The mean age at diabetes onset was 7.1 years (SD 4.4 years), and the mean duration of diabetes at documentation was 6.4 years (SD 4.5 years). Eleven (19%) of the patients with JIA and T1D were documented with an additional AID. Comorbid AIT and CD were reported in 6 (10.3%) patients 
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Volume 192 and 2 (3.4%) patients, respectively. One patient had autoimmune pancreatitis, and in 2 cases, the additional AID was "unknown" or "not confirmed." Nearly all patients with T1D were receiving insulin therapy (94.6%) with a mean daily dosage of 0.55 IU/kg (SD 0.29). Among the 15 patients with a low insulin requirement (≤0.5 IU/kg/day, mean T1D duration: 80.9 (SD 55.6) months), 4 patients (26.7%) were treated at documentation or during the prior year with a combination of methotrexate (MTX) and a biological DMARD (bDMARD), 1 patient (6.7%) was treated with a bDMARD, and 5 patients (33.3%) were treated with MTX alone. In contrast, in the group with a higher insulin requirement (>0.5 IU/kg/day, n = 14, mean T1D duration: 89.6 [SD 54.8] months), 2 patients (14.3%) were treated with MTX in combination with a bDMARD, 1 patient (7.1%) was treated with a bDMARD, and 6 patients (42.9%) were treated with MTX alone. Thus, approximately 60% of the patients in both groups were treated with MTX. However, patients with a low insulin requirement were more often treated with a bDMARD than patients with a higher insulin requirement (33.3% vs 21.4%, respectively). The duration of T1D was not significantly different between the groups (P = .668).
Information about the onset of both diseases was available for 54 (93.1%) of the 58 T1D cases; for 3 patients the T1D onset was unknown, and in 1 patient both the JIA and diabetes onset was missing. T1D occurred in 63% of the patients before the onset of JIA (mean 56.4 months; SD 42.6 months). In 37% of the patients, JIA symptoms preceded the onset of T1D by a mean of 40 months (SD 40.9 months).
We analyzed the cumulative distribution of the age at T1D onset of patients with JIA compared with the general population (Figure 2 ). T1D manifested earlier in patients with JIA compared with the reference population (means, JIA: 7.1 years; reference: 9.4 years). In the JIA group, 50% developed T1D before the age of 6 years, and in the general population 50% of T1D cases developed until the age of 9 years. We observed an earlier and faster slope for patients with JIA compared with the general population. However, after the age of 10 years, the rate of accumulation of new T1D cases in JIA diminished greatly, although the cumulative incidence in the general population continued to increase with age.
We divided the patients with JIA with comorbid T1D into 2 groups, T1D first (diabetes 1st , n = 34) and JIA first (JIA 1st , n = 20). Patient characteristics for the 2 groups are shown in group were an average of 3.2 years younger at the time of documentation (P = .01) and 7.6 years younger at JIA onset (P < .001) than patients in the diabetes 1st group. The age at T1D onset did not differ significantly between the groups. For the JIA 1st group, the mean JIA disease duration was significantly longer (P < .001), and the mean T1D duration was significantly shorter (P = .001) than that of the diabetes 1st group. Differences in the distribution of JIA categories, therapy, and anthropometric measurements were not statistically significant between the groups. Both groups did not differ significantly in functional disability, in the cJADAS-10 or in the physician's global assessment.
Information about DMARD treatment before T1D onset was available for 10 (50%) of 20 JIA 1st patients. Among those patients, 7 (70.0%) had not received any DMARD therapy. Three patients (30.0%) were treated with MTX before T1D onset, 2 of whom were also treated with systemic glucocorticoids. No patients were treated with a bDMARD before T1D onset. The patients with available data from previous years did not differ in the JIA category distribution, sex, age, disease duration, and age of onset of JIA and T1D from those patients with T1D without previous documentation.
Discussion
We analyzed the T1D occurrence in patients with JIA and characterized patients having JIA and T1D using data from a nationwide pediatric rheumatologic database. This study involved a large cohort of patients with JIA with comorbid T1D using a cross-sectional design. We found that the T1D prevalence was nearly twice as high in patients with JIA as in the general population. Comorbid T1D did not seem to affect the outcomes in patients with JIA. T1D onset in patients with JIA occurred earlier than in the general population and twothirds of patients with JIA and T1D developed T1D before JIA. No patient with JIA developed T1D after initiating bDMARD therapy.
Our results are comparable to findings of previously published studies. An American and a Finnish cohort study also investigated the occurrence of T1D in patients with JIA compared with population-based data.
6,31 T1D prevalence was 1.1% (5 of 443 patients) in the American cohort and 2.2% (9 of 417 patients) in the Finnish cohort. Our reported diabetes rate ratio was lower compared with these cohorts who found a 5-to 6-fold increase in the T1D prevalence in patients with JIA compared with the reference data. It should be noted that there is a north-south gradient of AIDs, and Finland has the world's highest T1D prevalence. 32 The results of the Finnish cohort were similar to our results in that the frequency of an additional AID (22%), AIT (14.6%), and CD (7%) in patients with JIA was comparable. These results support a genetic association of JIA with other AIDs.
Although we and others observed a higher prevalence of T1D in patients with JIA, Hermann et al studied comorbid JIA in T1D patients. 19, 20 Data showed a 4-fold increase in JIA prevalence among 54 911 patients with T1D compared with the general population. Thus, our results confirmed a higher risk for the development of T1D in patients with JIA, and the DPV diabetes register data confirmed a higher risk for the development of JIA in patients with T1D. 19 As in our data, the majority of patients with T1D and JIA from the DPV diabetes register developed T1D before the onset of JIA (88%).
Hermann et al compared patients with T1D and JIA with patients with T1D without JIA and found a decrease in weight (SDS 0.02 vs 0.22, respectively, P = .01). 19 Our data confirmed the results of the DPV diabetes register. Patients with JIA without T1D had a significantly lower body weight than patients with JIA and T1D, who had less negative body weight SDS, which translates to less of a decrease in body weight. The higher body weight of patients with JIA and T1D resulted in higher BMI SDS. A previous NPRD analysis of BMI in patients with JIA compared with population-based data in Germany did not reveal significant differences in general, 21 but the study showed an increased prevalence of a higher BMI in patients with systemic JIA and enthesitis-related arthritis. These categories are not distributed differently between patients with JIA with and without T1D; thus, the underlying cause for a higher BMI might be related to T1D-indicated insulin therapy, which is associated with weight gain. 34 Several studies have shown that DMARD use is associated with a significantly lower frequency of comorbid DM in patients with rheumatoid arthritis. 35 Hydroxychloroquine and antitumor necrosis factor therapy 37 also decreased the risk for development of DM in patients with rheumatoid arthritis. The investigations included patients with all DM diagnoses (International Classification of Diseases, Ninth Revision, Clinical Modification 250) including T1D. However, the majority of patients in these studies probably had T2D. The key mechanism in T1D pathogenesis is inflammation of pancreatic b cells and a linked expression of proinflammatory cytokines. 38, 39 The immunomodulatory effect of several medications was found to improve T1D outcomes 37, 40 and may potentially prevent T1D. [41] [42] [43] [44] [45] Asseldonk et al observed improved insulin sensitivity and a reduced insulin requirement in 14 patients with T1D who were treated with the interleukin-1 receptor antagonist anakinra for 1 week. 46 The effect lasted 4 weeks after the final application, which may be an explanation for the low insulin requirement of patients with JIA in our study cohort. The insulin requirement in patients with comorbidity of T1D and JIA was lower in the NPRD data than in the diabetes registry (0.55 IU/kg/day vs 1.03 IU/kg/ day, respectively). The subanalysis of our data revealed that patients with JIA with T1D and low insulin requirement were more frequently treated with bDMARDs, and patients with JIA and a higher insulin requirement were less often treated with bDMARDs (33.0% vs 21.4%, respectively). Unfortunately, we did not have information on the treatment of patients with JIA in the diabetes registry. Thus, the comparison of DMARD therapy between the registries remains open.
Compared with reference data from the general population, patients in our study with JIA and T1D had an earlier onset of diabetes. Hermann et al 19 found significantly earlier T1D manifestations in patients with comorbid JIA vs patients without JIA (median: 7.2 vs 8.3 years, respectively, P = .04). Regarding the age distribution of the cumulative T1D incidence (Figure 2) , we observed that the peak incidence of diabetes cases in the older age groups found in the general population data was absent in the JIA data. We speculate that the decreased occurrence of T1D in older patients with JIA may be associated with JIA-indicated DMARD therapy. Alternatively, the decreased T1D incidence may also be caused by "depletion of susceptibles." Predisposed patients may develop T1D at an early age because of a strong autoimmune phenotype.
Furthermore, we analyzed the treatment with glucocorticoids and DMARDs in patients with JIA diagnosed before T1D onset. Although the number of patients was small (n = 10), we observed that no patient in our cohort received bDMARD therapy before T1D onset, which may be linked to an association between DMARD therapy and the risk of T1D. Three patients were documented as previously being treated with MTX therapy; MTX alone does not seem to be associated with a reduced risk for DM in patients with JIA. 35 Bongartz et al hypothesized that the risk-reducing effect of DMARDs for DM is not based only on an anti-inflammatory effect but may be amplified by pathway-specific effects of immunosuppressive agents that induce an anti-hyperglycemic impact. 47 In summary, several findings in our study support the hypothesis, that bDMARD therapy may be associated with a lower incidence of T1D in patients with JIA. Patients with JIA with T1D who had a low insulin requirement were more often treated with bDMARD than patients with JIA with T1D who had a higher insulin requirement. The majority of T1D cases occurred before the onset of JIA and therefore, before JIA-indicated therapy. None of the cases of diabetes in our cohort (with available therapy data) were treated with a bDMARD before the onset of diabetes. The association between DMARD therapy in general, and bDMARD in particular, and a reduced risk for T1D should further be investigated in longitudinal analysis of a large, long-term prospective cohorts.
A limitation of our study is the small number of patients with T1D, especially for subgroup analysis such as insulin requirement. We may have underestimated the number of patients with T1D because we required validation of the DM diagnosis by a positive response to that item in the physician's questionnaire. Information on comorbid DM was not provided in one-fourth of the patients with JIA. Furthermore, the nationwide JIA data were compared with the reference data of the federal state of North Rhine-Westphalia. The T1D prevalence in North Rhine-Westphalia is higher than the estimated nationwide T1D prevalence, 25 which would result in a lower prevalence ratio.
Our analyses were based on diabetes data that were collected in the NPRD only from 2012 to 2014. Cross-sectional data do not allow many assertions about the disease course and other factors. Moreover, because of the NPRD study design, patients were documented at an arbitrary time during the disease course, which may have led to a variation in the time between the onset of JIA and outcome assessments at documentation. Nevertheless, most of our findings are supported by results of previous international studies.
In conclusion, our study in the NPRD and the study of Hermann et al in the diabetes registry confirm the clustering of JIA, T1D, AIT, and CD in large populations. 19 If a child or adolescent has developed JIA or T1D, the treating pediatrician should be aware of the increased risk for the development of the other AID. ■
